Kobayashi Tatsuya, Kida Yoshihisa, Hasegawa Toshinori
Department of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Japan.
Neurosurg Focus. 2003 May 15;14(5):e13. doi: 10.3171/foc.2003.14.5.14.
One hundred seven cases of craniopharyngiomas were treated using gamma knife surgery (GKS) at Komaki City Hospital during the past 12 years. The authors report the long-term results obtained in 100 patients who were followed for 6 to 148 months (mean 65.5 months).
All patients underwent GKS. The mean tumor diameter and volume were 18.8 mm and 5.8 ml, respectively; lesions were treated with a maximum dose of 21.8 Gy and marginal dose of 11.5 Gy (mean isocenters 4.5). Overall tumor responses were complete in 19, partial in 44, no change in 14, and disease progression in 23, yielding a complete response rate of 19%, overall response rate of 63%, control rate of 77%, and progression rate of 23%. Considering factors such as patient age, nature of the tumor (solid, mixed, cystic), frequency of previous treatments, and tumor size, the age and nature of the tumor were significant prognostic factors. Changes in neurological and pituitary-hypothalamic symptoms after GKS were evaluated in 91 patients. Overall improvement was demonstrated in 17 (18.7%), no change in 59 (64.8%), and deterioration in 15 (16.5%). Outcome was documented in 93 cases: excellent in 42, good in 23, fair in seven, poor in three, and dead in 18 patients.
Stereotactic GKS is a safe and effective treatment as an adjuvant or boost therapy for postresection residual and/or recurrent craniopharyngiomas; the effects are durable and side effects acceptable.
在过去12年中,小牧市立医院使用伽玛刀手术(GKS)治疗了107例颅咽管瘤。作者报告了100例患者的长期结果,这些患者的随访时间为6至148个月(平均65.5个月)。
所有患者均接受了GKS治疗。肿瘤平均直径和体积分别为18.8毫米和5.8毫升;病变的最大剂量为21.8 Gy,边缘剂量为11.5 Gy(平均等中心4.5)。总体肿瘤反应为完全缓解19例,部分缓解44例,无变化14例,疾病进展23例,完全缓解率为19%,总缓解率为63%,控制率为77%,进展率为23%。考虑患者年龄、肿瘤性质(实性、混合性、囊性)、既往治疗频率和肿瘤大小等因素,肿瘤的年龄和性质是重要的预后因素。对91例患者进行了GKS术后神经和垂体 - 下丘脑症状变化的评估。总体改善者17例(18.7%),无变化者59例(64.8%),恶化者15例(16.5%)。记录了93例患者的结果:优秀42例,良好23例,中等7例,差3例,死亡18例。
立体定向GKS作为切除术后残留和/或复发性颅咽管瘤的辅助或强化治疗是一种安全有效的治疗方法;效果持久且副作用可接受。